Investigational Valve System for Severe Aortic Regurgitation

Trial ID:
Curtiss Stinis, MD
This study will assess the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for the treatment of high surgical risk patients with symptomatic, severe aortic regurgitation (AR). Expected study duration: 72 months
Enrollment completion: Approx. 12 months. annual follow-up visits for 5 years.
*Be 18 years or older with severe aortic regurgitation as assessed by echocardiography<br>*Be symptomatic according to NYHA functional class II or higher<br>*Be at high risk for surgical aortic valve replacement <br>*Meet all other eligibility criteria

Contact Info:

  • Clinical Research Services